Ascendis Pharma's Q3 Loss, Revenue Surge

Ascendis Pharmas Q3 earnings report revealed a significant loss per share, with a loss of one euro per share compared to the predicted twenty-eight cents. However, revenue surged by 269% to €213.6 million, driven by Yorvipath and Skytrofa. Despite increased operating expenses due to global expansion, the company ended the quarter with €539 million in cash. The FDAs decision on TransCon CNP for treating children with achondroplasia is expected by November 30, 2025.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.